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Aberrant extra-vascular expression of VE-cadherin has been observed in metastasis
associated with Vasculogenic Mimicry (VM); we have recently shown that in VM
prone cells VE-cadherin is mainly in the form of phospho-VE-cadherin in Y658
allowing increased plasticity that potentiates VM development in malignant cells. In
the current study, we present results to show that human malignant melanoma cells
VM+, express the VE-cadherin phosphatase VE-PTP. VE-PTP forms a complex with
VE-Cadherin and p120-catenin and the presence of this complex act as a safeguard
to prevent VE-Cadherin protein degradation by autophagy. Indeed, VE-PTP silencing
results in complete degradation of VE-cadherin with the features of autophagy. In
summary, this study shows that VE-PTP is involved in VM formation and disruption
of VE-PTP/VE-Cadherin/p120 complex results in enhanced autophagy in aggressive
VM+ cells. Thus, we identify VE-PTP as a key player in VM development by regulating
VE-cadherin protein degradation through autophagy.
Keywords: vasculogenic mimicry (VM), VE-PTP, vascular endothelial receptor protein tyrosine phosphatase,
VE-cadherin, melanoma, autophagy
INTRODUCTION
The term vasculogenic mimicry (VM) describes the formation of perfusion pathways in tumors
by highly invasive, genetically deregulated tumor cells: vasculogenic because they distribute
plasma and may contain red blood cells and mimicry because the pathways are not blood
vessels and merely mimic vascular function. While VM formation is a marker of highly invasive
tumor phenotype, mechanisms by which these structures may contribute to adverse outcome are
not well-understood. It has been proposed that VM formation may facilitate tumor perfusion
and the physical connection between VM and blood vessels may also facilitate hematogeneous
dissemination of tumor cells. There is a strong association between the histological detection of
VM patterns in primary uveal and cutaneous melanomas and subsequent death from metastasis
(1, 2), consistent with the in vitro observations that these patterns are generated exclusively by
highly invasive tumor cells (3). ECs express various members of the cadherin superfamily, in
particular, vascular endothelial (VE-) cadherin (VEC), which is the primary adhesion receptor
of endothelial adherent junctions. Aberrant extra-vascular expression of VE-cadherin has been
observed in specific cancer types associated with VM (4). VE-PTP (vascular endothelial protein
tyrosine phosphatase) is an endothelial receptor-type phosphatase whose name was coined for
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its prevalence to bind to VE-cadherin (5). VE-PTP poise
endothelial barrier through helping homotypic VE-cadherin to
keep at minimum basal endothelial permeability (6). Knockdown
of VE-PTP increases endothelial permeability and leukocyte
extravasation (7). VE-PTP also counterbalances the effects
of permeability-increasing mediators such as VEGF, which
increase endothelial permeability and leukocyte trafficking, by
dephosphorylating VE-cadherin at Tyr658 and Tyr685, leading
to stabilization of VE-cadherin junctions (8, 9).
p120-catenin was initially described as an Src kinase substrate,
and then as a component of the cadherin-catenin complex.
p120-catenin promotes cadherin stability, lowering the complex’s
susceptibility to endocytosis, ubiquitination, and proteasomal
destruction (10). Phosphatases such as SHP-1, SHP-2, DEP1, and
RPTPµ act upon p120-catenin. The RPTPµ tyrosine phosphatase
binds p120 in a manner independent of p120’s central Armadillo
domain (11).
While studies have focused on the connection between VE-
PTP and VE-cadherin in ECs. No reports have determined the
role of VE-PTP in VM. Recent reports show that phospho-VE
cadherin is highly expressed in VM+ cells and facilitates their
pseudo-endothelial behavior by favoring p120/kaiso-dependent
gene regulation (12). In the current study, we elucidated a
mechanism linking VE-PTP expression with the induction of
VM in metastatic melanoma cells: VE-PTP is present in the
VE-Cadherin/p120 complex and the absence of VEPTP in this
complex leads to autophagy. These results place VE-PTP as a
dynamic component of VM transformation of melanoma cells
owing to its ability to retain/safeguard VE-cadherin from being
degraded by autophagy in aggressive cells.
RESULTS AND DISCUSSION
VE-PTP Expression Is Essential for
VE-Cadherin Stability and to Form VM
Aberrant extra-vascular expression of VE-cadherin has been
observed in specific cancer types associated with VM, and it has
previously been shown that most of the VE-cadherin present
in VM+ melanoma cells is phosphorylated form in Y658 (12).
The current study is focused on the role of the phosphatase
VE-PTP, its interaction with non-endothelial VE-cadherin and
its consequences in VM development. Total VE-cadherin and
VE-PTP expression were measured in different melanoma cell
lines from either cutaneous (C8161, C81-61) or uveal (MUM 2B,
MUM 2C) origin as shown in Figure 1A (protein) and Figure 1B
(mRNA). Recently, our group reported that human malignant
melanoma cells have a constitutively high expression of pVE-
cadherin at position Y658, pVE-cadherin Y658 is a target of
focal adhesion kinase (FAK) and forms a complex with p120-
catenin and the transcriptional repressor Kaiso in the nucleus
(12). We have also shown that FAK inhibition enabled Kaiso
to suppress the expression of its target genes and enhanced
Kaiso recruitment to KBS-containing promoters (CCND1 and
WNT 11). Silencing of VE-PTP induced a significant reduction
of CCND1 and WNT 11 (Kaiso-dependent genes) (Figure 1C)
and disrupted VM formation quantified by Wimasis program
(Figures 1D,E) suggesting that VE-PTP was also involved in
the intracellular dynamic of VE-cadherin resulting in the
regulation of Kaiso-dependent genes. To evaluate the correlation
between the levels of VE-PTP and VE-cadherin we performed
a western blot after siVE-PTP in MUM 2B (Figure 1F) and
found an almost complete vanishing of VE-cadherin and
pVE-cadherin suggesting that VE-PTP was involved in VE-
cadherin stability and was needed for pVE-cadherin to reach
the nucleus, as indirectly suggested the results obtained in
Figure 1C. Interestingly, a completely different situation was
found in primary endothelial cells HUVEC where siVE-PTP
leads to an accumulation of pVEC in both cytosolic and
nuclear compartments (Figure 1G). These results suggested that
VE-PTP in malignant melanoma cells was protecting pVEC
from degradation.
VE-Cadherin and VE-PTP Form a Complex
With p120 Catenin in Melanoma Cells
The VE-cadherin-catenin complex provides the backbone of
the adherent junction in the endothelium. Nonetheless, in non-
endothelial cells, the proteins interacting with VE-cadherin have
not been identified. Using a coIP or co-immunofluorescence
(Figure S1A) approach to analyse the VE-cadherin and VE-PTP
interacting proteins showed that VE-Cadherin forms a fragile
complex with VE-PTP in MUM2B (Figures 2A,C) compared
with the stronger complex in HUVECs (used as a positive control
on VE-PTP/VE-Cadherin complex in normal endothelial cells)
(13) (Figure 2B). Surprisingly, the presence of p120-catenin in
complex with VE-PTP appears in MUM2B cells as compared to
HUVEC cells (Figures 2B,C) suggesting that VE-PTP might be
involved in the control of p120-catenin phosphorylation status in
melanoma cells. To analyse the possible impact of p120 on VE-
cadherin stability in MUM2B, cytosol-nucleus subfractionation
assay after silencing p120, found that p120 protect the stability
of VE-cadherin (Figure 2D). Finally, we performed a coIP of
p120 after siVE-PTP in MUM 2B cells, and we observed that
binding of VE-cadherin to p120 was lost and resulted in increased
global tyrosine phosphorylation of p120, suggesting that VE-
PTP safeguard of VE-Cadherin/p120 binding in VM+ cells
by balance between phosphorylation and dephosphorylation of
p120 through VE-PTP activity (Figure 2E) and p120-catenin
is likely to be a substrate for VE-PTP. These results are
compatible with the increased phospho-p120 (as result of VE-
PTP inactivation) being responsible for complex dissociation to
initiate VE-cadherin proteolysis. In fact, it has been described
that only isoform 1A of p120 can be substrate of RPTPmu,
correlating with the results in Figure 2C (increased binding of
VE-PTP to isoform 1A of p120) and 2E (see the band with the
arrow corresponding to pY-p120 in the blot for global p-Try
(4G10) in the immunoprecipitation of p120).
VE-Cadherin/VE-PTP Complex
Dissociation-Enhanced Autophagy
To elucidate themechanism leading to VE-Cadherin degradation
after the inhibition of VE-PTP, we treated MUM2B cells
with proteasome inhibitor lactacystin or MG-132 (Figure S1B)
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FIGURE 1 | VE-PTP expression is essential for VE-cadherin stability and to form VM. (A) The expression of VE-PTP in aggressive (MUM 2B and C8161) and in
non-metastatic (MUM 2C and C81-61) melanoma cells (B) RNA expression of VE-PTP MUM 2C cells (C) expression of kaiso-dependent genes (CCDN1 and WNT11)
after silencing of VE-PTP decrease CCND1 and WNT 11 (Kaiso dependent genes) (D,E) siVE-PTP abolish the capacity to form in vitro VM in aggressive melanoma
cells; images were acquired using an Olympus CKX41 microscope (bars 500µm, the formation of tube-like structures was then quantified by Wimasis program. Each
treatment was performed in triplicate, and the experiment was independently repeated at least three times. Results represented as fold enrichment over input.
Asterisks denote statistically significant differences in an unpaired t-test (p < 0.05, **p < 0.01, ***p < 0.001), and error bars denote SD, (F) to confirm the implications
of VE-PTP in VM, we performed a siVE-PTP, and we show almost total decrease of VE-cadherin and Y658 expression in MUM 2B, (G) siVE-PTP in HUVEC in
cytosol-nucleus subfractionation experiments showing the phosphorylation of Y658 VE-Cadherin.
and did not prevent VE-Cadherin degradation after VE-PTP
disabling (Figure 3A) suggesting a proteasome-indenpendent
pathway. Macroautophagy (referred to only as “autophagy”) is
a homeostatic “self-eating” pathway that has been conserved
among eukaryotic cells. This is a lysosomal-associated process
in which intracellular components, small portions of cytosol or
chaperone-associated cargo, are engulfed in double-membrane
vesicles, called autophagosomes, to be degraded with lysosomal
hydrolyses (14). Recently, different studies reported that the
formation of VM was promoted by bevacizumab-induced
autophagy in GSCs, which was associated with tumor resistance
to antiangiogenic therapy through the high expression of
VEGFR-2 (15). In our study, inhibition of the fusion of
autophagosomes and lysosomes with chloroquine suppressed
the degradation of VE-cadherin after siVE-PTP (Figure 3A and
Figure S1C). Even more, the levels of the mTOR substrate p-p70
(as a readout of mTOR activity and autophagy status) decreased
in MUM 2B knockout for VE-cadherin (Figure 3B) suggesting
that the complex VE-cadherin/VE-PTP might be restraining
autophagy. Electron microscopy experiments (Figure 3C) were
performed in MUM 2B and C8161 cell deficient for siVE-
PTP or MUM 2B knockout for VE-cadherin; these results
showed an enhanced autophagic morphology after the VE-
PTP silencing or in VE-cadherin knockout cells, suggesting
that the absence of either protein may have implications in
the dynamic of protein turnover involoving the activation of
autophagy. To confirm the implication of autophagy on VE-
cadherin degradation, we quantified autophagosomes formation
under the same conditions described above after transfection
of LC3-GFP and observed that the number of autophagosomes
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FIGURE 2 | VE-Cadherin and VE-PTP form a complex with p120 catenin in melanoma cells: (A) immunoprecipitation of VE-Cadherin and VE-PTP in MUM 2B
showed a little union of both proteins in VM cells, (B) in contrast, in endothelial cells (HUVEC) both proteins showed a robust interaction. (C) p120 interact with
VE-PTP and VE-cadherin in immunoprecipitation experiments in MUM 2B (D) cytosol-nucleus subfractionation with scb and sip120 shown that the stability of
VE-cadherin as well the phosphorylation of Y658 is p120-dependent, (E) p120 immunoprecipitation after VE-PTP silencing produce a high increase onto p120
phosphorylation and decrease the binding of VE-cadherin.
(LC3-GFP punctuated) increased following silencing of VE-
PTP in both MUM 2B and C8161 VM+ cells (Figure 3D and
Figure S2C). By analyzing the cBioPortal database, a platform of
48333 tumor samples, we found that highmRNA levels of PTPRB
(the gene encoding for VE-PTP) were inversely associated with
the expression of two essential genes involved in autophagy,
LAMP1 and ATG7 in uveal melanoma (Figure S2D), suggesting
that in patients this interaction might be relevant to determine
autophagic features of the tumor.
While the role of VE-cadherin as a determinant of the
pseudo-endothelial behavior of malignant melanoma cells
have been widely described, no studies have addressed
so far the implications of VE-PTP in VM development.
Previous results have reported that VE-cadherin in VM-prone
tumor cells is mostly as pVE-cadherin (Y658) and in several
intracellular locations (including the nucleus) conferring
the cells with the necessary plasticity to undergo pseudo-
endothelial differentiation (12). To get further information on
the cause of these phosphorylated VE-cadherin population, we
focalized in the phosphatase VE-PTP that keeps VE-cadherin
unphosphorylated in endothelial cells. Despite the massive
amounts of VE-cadherin, VE-PTP levels in melanoma cells
were sharply diminished, suggesting that a majority of the
VE-cadherin population is not in complex with VE-PTP (as
compared with endothelial cells Figures 2A,B), then tolerating
the accumulation of pVE-cadherin while endothelial cells tight
junctions require a stable and abundant VE-PTP/VE-cadherin
complex to keep vascular permeability strictly under control. In
aggressive melanoma cells, that not presence (VE-PTP null cells)
of unbound VE-Cadherin to VE-PTP initiates the proteolysis
of VE-cadherin trough autophagy (increase p-p120) and finally
decrease VM capacity or the reverse situation VE-PTP positive
cells, increase the capacity to form VM (Figure 4). The question
remains how a relatively small amount of VE-PTP protects
from proteolysis and what signal emerges from the complex
dissociation to activate autophagy. Contrary to endothelial cells,
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FIGURE 3 | VE-Cad/VE-PTP complex dissociation-enhanced autophagy: (A) inhibition of proteasome with lactacystin (30µM during 30min) with or without siVE-PTP
or inhibition of autophagy with chloroquine treatment (20µM during 3 h) (C) electron microscopy experiments in control (scrambled), siVE-PTP and MUM 2B K.O;
autophagosomes are shown with arrows (bars: 1µm), (B) Western blot of p-p70 and LC3-II (D) quantification of autophagosomes (LC3-GFP punctuated cells)
following silencing of VE-PTP in both MUM 2B and C8161 VM+ cells, each treatment was performed in triplicate, and the experiment was independently repeated at
least three times. Results represented as fold enrichment over input. Asterisks denote significance in an unpaired t-test (p < 0.05, **p < 0.01, ***p < 0.001), and error
bars denote SD.
p120-catenin is also firmly attached to VE-PTP in MUM 2B cells
(Figures 2B,C), and the loss of this complex (after siVE-PTP
silencing) leads to p120-catenin increased phosphorylation and
VE-cadherin degradation by disunity of p120. Globally these
results shed light to a newmechanism to control VM through the
balance between VE-PTP/VE-cadherin and the phosphorylation
status of p120 in aggressive melanoma VM+ cells.
MATERIALS AND METHODS
Reagents and Antibodies
The following reagents were used: Chloroquine 100µM during
3 h, Lactacystin 30µM during 30min and MG-132 3µM
during 3 h. Corning Matrigel Basement Membrane Matrix
for in vitro angiogenesis experiments. Antibodies used were:
Y658 VEC rabbit (1:1000WB, 1:100 IF, Thermofisher), VEC
C-ter mouse (1:500WB, 1:50 IF, 2µg IP, clone F-8, sc-9989),
anti-phosphotyrosine p-Tyr mouse (1:1000WB, clone 4G10,
Millipore), α-tubulin mouse (1:10000WB, clone B-5-1-2, Sigma-
Aldrich), p120 catenin mouse (1:1000WB, 1:100 IF, 2µg IP,
BD Biosciences), lamin B1 rabbit (1:1000WB, Abcam) and
VE-PTP mouse (1:1000WB,1:100 IF, 2µg IP, Clone 12/RPTPb,
BD Biosciences).
Cell Lines
Human melanoma cells MUM 2B, MUM 2C, C8161, and
C81-61 were grown in RPMI medium supplemented with
10% fetal bovine serum, 2mM of L-glutamine, and 1%
penicillin/streptomycin (PAA laboratories). Human umbilical
vein endothelial cells (HUVEC) were grown in endothelial cells
growth medium-2 (EGM-2) (Lonza). All cells were cultured at
37◦C and 5% CO2 in incubator cells.
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FIGURE 4 | Main signaling pathways involved in vasculogenic mimicry in VE-PTP/VE-Cad null or positive, aggressive melanoma cells.
In vitro Angiogenesis Assay
The effect of siVE-PTP on the formation of tube-like structures
in Matrigel (BD Biosciences) was determined according to the
manufacturer’s instructions. Briefly, 96-well plates were coated
with 50µl of BD MatrigelTM Basement Membrane Matrix and
allowed to solidify at 37◦C in 5% CO2 for 30min. Cells
were treated Scb, siVE-PTP transfected for 48h as described
previously. After 48 h, respectively, of incubation, images were
acquired using an Olympus CKX41 microscope (10X lens). The
formation of tube-like structures quantified byWimasis program.
Each treatment was performed in triplicate, and the experiments
independently repeated at least three times.
Quantitative RT-PCR
Total RNA was isolated by RNeasy Mini Kit (Qiagen)
according to the manufacturer’s recommendations. About
1µg of RNA from each sample was treated with DNase I,
RNasinRibonuclease inhibitors (Invitrogen) and reverse-
transcribed using iScriptcDNA synthesis kit (Biorad) following
the manufacturer’s protocols. cDNA was amplified using the
iTaq Universal SYBR green supermix (Biorad). Each reaction
was performed in triplicate using CFX96 Real-time PCR
detection systems. Primer sequences for the targets and the
annealing temperature (60◦C): 36B4: Forward 5′-CAGATT
GGCTACCCAACTGTT-3′, Reverse 5′-GGCCAGGACTCGT
TTGTACC-3, CCND1: Forward 5′-CCGTCCATGCGGA
AGATC-3′, Reverse 5′-GAAGACCTCCTCCTCGCACT-3′;





MUM2B knockout (ko) cells for the VE-Cad gene were
generated using the CRISPR-Cas9 technology. Five different
sgRNAs were designed using the Zhang Lab Optimized
CRISPR design tool and cloned into the pL-CRISPR.EFS.GFP
which purchased from the Addgene public repository
(#57818). sgRNA guides were validated in HEK293T
Cells using the GeneArt Genomic Cleavage Detection Kit
(Invitrogen, Carlsbad, USA) according to the manufacturer’s
instructions. Lentiviral particles for the best two sgRNAs in
terms of allelic disruption (GGCAGGCGCCCGATGTGGCG
and GATGATGCTCCTCGCCACATC).
Transfection of Small Interfering siRNA
Cultured cells were transiently transfected with an irrelevant
siRNA (5′-CCUACAUCCCGAUCGAUGAUG-3′) 50 nM. siVE-
PTP: 5′- GACAGUAUGAGGUGGAAGU−3′, 50 nM, sip120:
5′- GGATCACAGTCACCTTCTA−3′, 50 nM, were transfected
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For simple coimmunoprecipitation, cells were lysed in lysis buffer
(50mMTris/HCl ph 8, 120mMNaCl, 0,1 %NP-40, 1mMEDTA,
10mM NaF, 1mM Na3VO4 and supplemented with a protease
inhibitor cocktail (1 tablets to 10ml of lysis buffer, Roche) for
30min at 4◦C. Lysates were cleared by 13.000 rpm centrifugation
for 10min at 4◦C and incubated overnight at 4◦C with respective
antibodies. Consequently, the next day, IP lysates were incubated
for 2 h at 4◦C with 50µl of-of DynabeadsTM Protein G for
Immunoprecipitation (ThermoFischer). Dynabeads were washed
three times with low salt 120mM lysis buffer and two times with
high salt 300mM lysis buffer. All lysates separated by dodecyl
sulfate-polyacrylamide (7,5%, Biorad) gel electrophoresis and
transferred to PVDF membrane (Pall laboratory) by semi-
wet blotting.
Accordingly with the article of Rockstroh et al. (16), for
subfractionation cytosol-nucleus, cells were lysed in lysis buffer
(250mM sucrose, 50mM Tris-HCl ph 7,4, 5mM MgCl2,
1mM Na3VO4, 0,25 % NP-40 and supplemented with a
protease inhibitor cocktail (1 tablet to 10ml of lysis buffer,
Roche) for 10min at 4◦C, lysates centrifuged at 500 g for
5min, supernatant was considerate cytosolic fraction, pellet
was resuspended in buffer 2 (1M sucrose, 50mM Tris-HCl
ph 7,4, 5mM MgCl2) and centrifuged at 3,000 g for 5min,
supernatant was discarded. Pellet was resuspended in nuclear
buffer (20mM Tris-HCl ph 7,4, 0,4M NaCl, 15% glycerol,
1,5% Triton X-100) for 45min at 4◦C in agitation. This lysate
centrifuged at 5,000 g for 5min; the supernatant was considered
a nuclear fraction.
Immunofluorescence
Immunostaining was performed on cells plated onto coverslips
and grown for 24 h prior to experimental treatment. The cultured
media was removed and wash two times with PBS 1X and
the cells were fixed (Paraformaldehyde 3%, 5% sucrose) for
15min at room temperature. Permeabilization was performed
using 0,25% Triton-100 in PBS for 10min. Before start with
the antibodies incubation, cells were blocked with BSA 2% for
1 h. Respective primary antibodies were incubated for 45min
and secondary antibodies Alexa Fluor 488 anti-mouse (1:500,
green) or Alexa Fluor 594 anti-rabbit (1:250, red) were incubated
for 20min. Nuclear counter staining with 4′,6′-diamidino-
2-phenylindole dihydrochloride (DAPI) was performed after
removal of secondary antibody. Immunofluorescence images
were obtained in the linear range of detection to avoid signal
saturation using a fluorescent microscoper confocal microscopy
(Leica SP5, 63X lens).
Electron Microscopy
The MUM 2B extracted were washed with PBS, prefixed for
30min in a fixation solution (0.1M cacodylate buffer pH 7.4
and osmium tetraoxide) for 60min at 4◦C. After this treatment,
tissues were washed with MilliQ water, and the samples were
stained with uranyl acetate. The ultrathin sections were cut with
a diamond knife in an ultramicrotome (Reichert Ultracut S). The
samples were analyzed in a TEM Zeiss 902 with 80KV of voltage
acceleration (CIC-UGR).
Autophagy Assay
GFP-LC3-expressing cells have been used to demonstrate the
induction of autophagy. The GFP-LC3 expression vector was
kindly supplied by Dr T Yoshimori (National Institute for
Basic Biology, Okazaki, Japan). MUM 2B and C8161 were
transiently transfected (0,5µgr) with this vector together with
jetPrime (Polyplus transfection, Illkirch, France) according to
the manufacturer’s protocol. The assay was performed on cells
grown in six-well plates. To determine LC3 localization, GFP-
LC3-transfected cells were observed under a Zeiss (Zeiss Axio
Imager A1) fluorescence microscope (20X lens). To determine
LC3-II translocation, performed western blot of LC3-I and its
proteolytic (phosphatidylethanolamine) derivative LC3-II (18
and 16 kDa, respectively) using a monoclonal antibody against
LC3 (NanoTools,1:1000WB, 1:100 IF, clone 5F10, Ref 03231-
100/LC3-5F10).
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Figure S1 | (A) Co-immunofluorescence of VE-PTP (green) and VE-Cadherin
(red), DAPI (nuclear stain, blue) in MUM 2B cells. Bars 15µm. (B) Inhibition of
proteasome through MG-132 (3µM during 3 h) with or without siVE-PTP
conditions not prevent the VE-cadherin degradation. (C) Co-immunofluorescence
of Y658 VE-Cadherin (red) and LC3 I/II (green) with or without siVE-PTP
(Cloroquine treatment: 20µM during 3 h) conditions in MUM 2B cells. Bars 15µm.
Figure S2 | (A) Quantification of autophagosomes (LC3-GFP punctuated cells) in
MUM 2B cells and C8161 cells after LC3-GFP transfection (0.5µgr). (B)
cBioPortal database, a platform of 48,333 tumors samples, we found that high
mRNA levels of PTPRB, associated with the expression of two essential
autophagy genes, ATG7 and LAMP1 in uveal melanoma samples.
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